Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

BI2536

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Boehringer Ingelheim

Drug class:

PLK1 inhibitor, BRD4 inhibitor

Related drugs:

CCNA2 expression	Gastric Cancer	CCNA2 expression	Gastric Cancer	BI2536 Sensitive: D – Preclinical BI2536 Sensitive : D	BI2536 Sensitive: D – Preclinical BI2536 Sensitive : D
FGFR1 amplification	Lung Cancer	FGFR1 amplification	Lung Cancer	ABSK091 + NBL-001 + BI2536 Sensitive: D – Preclinical ABSK091 + NBL-001 + BI2536 Sensitive : D	ABSK091 + NBL-001 + BI2536 Sensitive: D – Preclinical ABSK091 + NBL-001 + BI2536 Sensitive : D
FGFR1 amplification	Lung Cancer	FGFR1 amplification	Lung Cancer	NBL-001 + BI2536 Sensitive: D – Preclinical NBL-001 + BI2536 Sensitive : D	NBL-001 + BI2536 Sensitive: D – Preclinical NBL-001 + BI2536 Sensitive : D